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Abstract
Artemisinin resistance constitutes a major threat to the continued success of control programs
for malaria. With alternative antimalarial drugs not yet available, improving our understand-
ing of how artemisinin-based drugs act and how resistance manifests is essential to enable
optimisation of dosing regimens in order to prolong the lifespan of current first-line treatment
options. Here, through introduction of a novel model of the dynamics of the parasites’ response
to drug, we explore how artemisinin-based therapies may be adjusted to maintain efficacy and
how artemisinin resistance may manifest and be overcome. We introduce a dynamic mathe-
matical model, extending on the traditional pharmacokinetic-pharmacodynamic framework, to
capture the time-dependent development of a stress response in parasites. We fit the model
to in vitro data and establish that the parasites’ stress response explains the recently identified
complex interplay between drug concentration, exposure time and parasite viability. Our model
demonstrates that the previously reported hypersensitivity of early ring stage parasites of the
3D7 strain to dihydroartemisinin (DHA) is primarily due to the rapid development of stress,
rather than any change in the maximum achievable killing rate. Of direct clinical relevance,
we demonstrate that the complex temporal features of artemisinin action observed in vitro have
a significant impact on predictions of in vivo parasite clearance using PK–PD models. Given
the important role that such models play in the design and evaluation of clinical trials for al-
ternative drug dosing regimens, our model contributes an enhanced predictive platform for the
continued efforts to minimise the burden of malaria.
Keywords: artemisinin action, Plasmodium falciparum, drug exposure time, dynamic
model
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Introduction
Plasmodium falciparummalaria is a major vector-borne parasitic disease affecting over 200 mil-
lion people annually (1). Over the past two decades artemisinin-based therapies, used as the
first line treatment against falciparum malaria, have been shown to be highly effective. Their
widescale distribution (approximately 390 million treatment courses delivered annually) has
been instrumental in achieving a dramatic reduction in morbidity and mortality through both
individual-level clinical and public health benefits (1). Worryingly, over the past decade P.
falciparum parasites resistant to artemisinin derivatives—originally defined via a clinical phe-
notype of delayed clearance following treatment and now characterised by presence of the K13
mutation—have begun to emerge and spread across South East Asia (2, 3, 4, 5). With no new
antimalarial drugs yet available, and alternatives unlikely to be brought to market within the
the next few years, advancing our understanding of the antimalarial action of the artemisinins
is essential to prolong the lifespan of the current first-line treatment for malaria.
A model-based study of clinical isolates from Pailin (Western Cambodia) by Saralamba et
al. in 2011 demonstrated that artemisinin-resistant parasites displayed a reduced sensitivity to
artesunate (an artemisinin derivative with active metabolite dihydroartemisinin) during the ring-
stage of infection (6). Recent in vitro experiments have further demonstrated that P. falciparum
exhibits a distinct stage-dependent susceptibility to artemisinin, and that resistant isolates show
a reduced drug susceptibility during the very early ring stage of development (7, 8, 9). De-
spite this developing understanding of the subtleties of artemisinin action and drug resistance,
a major gap remains in describing the full dynamics of the host-pathogen-drug system and
translating findings from the well-controlled in vitro experimental environment to the in vivo
context.
Pharmacokinetic–pharmacodynamic (PK–PD) modelling, which integrates drug kinetics
(e.g. absorption and elimination) with the dynamics of both cyclic parasite growth and drug–
parasite interactions, enables the quantitative assessment of drug efficacy, determination of
optimal dosing schemes and the advancement of our understanding of antimalarial action and
resistance (10, 11, 12, 6, 13, 14, 15, 16, 17, 18, 19). Over nearly 20 years of development,
PK–PD models have increased significantly in complexity. Building from early models, which
treated infected red blood cells as a single compartment (10, 11, 12), models have expanded
to capture the different stages of the parasite life cycle in the red blood cell (ring, trophozoite,
schizont) allowing the incorporation of stage-dependent drug effects (6, 13, 19). A feature
common to all PK–PD models of artemisinin-based therapy developed to date has been the
implicit assumption that the relationship between drug concentration and the rate of parasite
killing is independent of the history of exposure. The transient killing rate k (i.e. the fraction
of parasites killed by drug per unit time) has been empirically modelled by a Hill function of
plasma drug concentration (C),
k(C) =
kmaxCγ
Kcγ +Cγ
, (1)
where parameters kmax, γ and Kc are (possibly stage-dependent) fixed quantities (i.e. constants)
(20). The killing rate varies with drug concentration in a sigmoidal manner and saturates at the
maximum killing rate kmax for high drug concentration. Under this formulation a higher drug
concentration will immediately exert a stronger killing effect.
However, the recent in vitro experiments of Klonis et al. (7) and Dogovski et al. (9) have
provided clear evidence that a higher drug concentration may not result in an increased killing
effect and indeed may be less effective if the exposure time is shortened. They demonstrated
that the fraction of parasites that remains viable (i.e. able to asexually reproduce and so initi-
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ate a subsequent round of blood-stage infection) does not depend solely on the applied drug
concentration. Rather, viability was established to be a complex function of the cumulative
drug exposure and the initial drug concentration, manifesting as (stage-dependent) variations
in the exposure time required to render parasites non-viable (7). The minimum exposure time
required for loss of viability was particularly extended for mid-ring stage parasites (artemisinin
sensitive 3D7 laboratory strain). Antimalarial resistance corresponded to a distinct change in
the susceptibility of early ring-stage parasites (9). To date, these novel properties have not been
incorporated into a mechanistic model of parasite killing, indicating a requirement to extend the
PK–PD modelling framework to reflect our emerging understanding of drug activity and eval-
uate the influence of these novel biological phenomena on the prediction of parasite clearance
(20).
Drug exposure time (h)
0 1 2 3 4 5 6 7
V
ia
b
ili
ty
0
0.2
0.4
0.6
0.8
1
1.2
Time (h)
0 2 4 6
D
H
A
 c
o
n
c
. 
(n
M
)
20
25
30
35
40
Drug exposure time (h)
0 1 2 3 4 5 6 7
V
ia
b
ili
ty
0
0.2
0.4
0.6
0.8
1
1.2
early ring
mid ring
early troph
late troph
Time (h)
0 2 4 6
D
H
A
 c
o
n
c
. 
(n
M
)
150
200
250
300
350A B
Figure 1: Representative experimental data showing how the fraction of viable parasite (i.e.
viability) changes with the duration of drug exposure for two different initial DHA concentra-
tions (39 nM (left) and 300 nM (right)) and four different parasite life stages. Insets indicate
the in vitro decay of DHA concentration. Empty circles display the raw viability data and the
curves pass through the arithmetic means of the paired data points. (Data sourced from (7).)
In this paper, we generalise the traditional model of killing (Eq. 1) by allowing the max-
imum killing rate kmax and the half-maximal killing concentration Kc to be time-dependent
quantities and then fit the generalised model to viability data for the 3D7 laboratory strain
available in (7). By doing so, we aim to 1) show if the model is able to capture the full set of in
vitro viability data; and 2) elucidate how the artemisinin-mediated killing effect develops fol-
lowing drug exposure and how that development differs between the parasite life stages. These
results will further imply the relative contributions of drug concentration and exposure time to
the effective killing rate. Finally, we incorporate the time-dependent drug effect into a PK–PD
modelling framework to evaluate its effect on in vivo parasite killing. Complex temporal effects
are anticipated to be present as the short half life of the artemisinins in vivo is comparable to
the exposure time required for effective parasite killing.
Materials and Methods
In vitro experiments and data
In order to identify the key features that motivate the development of our model, we first review
the in vitro experimental procedure (see (7) for details). Cultures containing equal quantities
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of tightly age-synchronised P. falciparum parasites (3D7 laboratory strain; over 80% of para-
sites synchronised within a one-hour age window) were treated with a specified dose of dihy-
droartemisinin (DHA) for a duration of 1, 2, 4 or 6 hours before washing (to remove all drug).
To quantify the effect of drug a viability assay was performed. Viable parasites were defined
as those able to reproduce and enter the next cycle of replication (thus excluding dead and dor-
mant populations), assessed by measuring the parasitaemia (P) in the trophozoite stage in the
following life cycle, 48 hours later. In order to calculate the viability, parasitaemia was also
measured for two special cases: the control case (Pcontrol) where no drug was applied; and the
background case (Pbackground) with supermaximal DHA concentration (> 10× the 50% lethal
dose of 3 days, nM) applied for over 48 hours. Viability (V ), a ratio and so unitless, was then
given by subtracting the unviable population,
V =
P−Pbackground
Pcontrol−Pbackground . (2)
To study stage-specific drug effects, Klonis et al. (7) tested four different parasite ages (by using
different age-synchronised groups): 2 hours post-infection (h p.i.; early ring stage), 7.5 h p.i.
(mid-ring stage), 24 h p.i. (early trophozoite stage) and 34 h p.i. (late trophozoite stage). Two
examples of viability data are given in Fig.1 which show the viability for different durations of
drug exposure (1h, 2h, 4h, and 6h) with an initial DHA concentration of approximately 39 nM
or 300 nM. Note that DHA concentration also decays in vitro with a half life of approximately
8 hours. Experiments were performed in technical replicates for each combination of initial
DHA concentration and drug exposure duration.
The model
We take as our fundamental conceptualisation of antimalarial action that the drug kills or oth-
erwise prevents parasites within infected red blood cells (iRBC) from being able to produce
viable merozoites (which would go on to invade and infect other RBC at the end of the first
life cycle.) We model the number of iRBC of age a (i.e. RBCs that have been infected with
parasites for a hours) surviving drug exposure (N(a, t)) by the first-order partial differential
equation,
∂N(a, t)
∂ t
+
∂N(a, t)
∂a
=−kN(a, t), (3)
where k is a drug-induced parasite killing rate and may depend on other factors such as drug
concentration, parasite life stage or even drug exposure duration (which will be explicitly indi-
cated once we formally introduce those dependencies later). We have the boundary condition
N(0, t) = rN(48, t), where r is the parasite multiplication factor, indicating the average number
of newly-infected RBC generated from merozoites released from a single iRBC at the end of
the preceding life cycle.
The in vitro experiments use tightly age-synchronised parasites, allowing for further sim-
plification to an ordinary differential equation system which is sufficient for determining the
time-dependency in the maximum killing rate kmax and the half-maximal killing concentration
Kc. We track only the number of newly infected RBC generated from parasites first exposed to
drug at age a¯ (denoted by N¯(t)):
dN¯(t)
dt
=−kN¯(t). (4)
As mentioned in the Introduction, the parasite killing rate k is empirically modelled by a Hill
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function of drug concentration (C(t)),
k(C(t)) =
kmaxC(t)γ
Kcγ +C(t)γ
, (5)
where kmax is the maximum killing rate, Kc indicates the drug concentration at which half
maximal killing, kmax/2, is achieved and γ is the Hill coefficient. To capture the time-dependent
features of the in vitro data, we generalise the model by allowing kmax and Kc to be dependent
on the duration of drug exposure. We consider the time-variation to be a function of an auxiliary
modulatory variable S(t) which we will refer to throughout as a general cell “stress”. During
drug exposure, parasites develop a stress response, the extent of which determines the killing
effect (and thus the concentration-killing rate function, Eq. 5). The stress, S(t), is normalised
to vary between 0 and 1 (inclusive). We consider S to increase in the presence of drug above
some (very small) threshold level C∗ but decrease once drug concentration C is below C∗. For
the increase phase, we apply a simple first-order differential equation:
dS
dt
= λ (1−S), (6)
where λ is a rate constant which sets the time-scale for stress development. In the absence of
additional experimental data, S(t) is assumed to immediately reset to zero once drug concen-
tration falls back below C∗. While this is sufficient to capture all available in vitro data, we
anticipate that further experimental research will allow us to more closely tie empirical deter-
minations of the mechanisms of stress and its accumulation to our modulatory variable S (with
consequential changes to Eq. 6.)
With S defined, we then model kmax and Kc as functions of S. kmax is evidently positively
correlated with S and Kc negatively correlated, indicating that as stress accumulates, the ability
of the drug (at a given concentration) to kill parasites increases. In the absence of detailed
experimental data, we assume these relationships are linear:
kmax = αS, (7)
and
Kc = β1(1−S)+β2, (8)
where α , β1 and β2 are parameters to be determined.
Under this simple formulation of the model for stress accumulation and the linear relation-
ship between stress and killing, we can solve Eq. 6 to obtain:
S(t) = 1− e−λ t , (9)
and thus
kmax = α(1− e−λ t), (10)
and
Kc = β1e−λ t +β2. (11)
Of note, when λ →∞ (i.e. the modulatory variable reaches its steady state instantaneously),
kmax = α and Kc = β2 such that our model reduces to a traditional PK–PD model with a fixed
relationship between drug concentration and killing rate.
For finite λ , kmax and Kc become functions of S and so duration of exposure. In particular,
for low λ , our model displays a slow development of the stress response and is thus capable
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of capturing a delayed reduction in viability, indicating its potential suitability for the in vitro
data shown in Fig. 2 and detailed in (7, 9). For simplicity, in this paper we now refer to the
traditional killing rate model with constant (although perhaps stage-dependent) kmax and Kc as
the stationary model and refer to our generalised model as a dynamic stress model.
The dynamic stress model contains five parameters (λ , γ , α , β1 and β2) to be determined
by fitting to available data. These five parameters are assumed to be stage-specific, and thus the
model is fitted separately to the viability data for each parasite stage. Note that, by incorporating
the phenomenological model of stress through the modulatory variable S, we aim to develop
a better understanding of how the killing rate evolves in the presence of drug. While we are
as yet unable to explore the underlying mechanisms governing the development of both stress
and drug action (e.g. the changes at the cellular or even molecular levels), we discuss possible
biological interpretations further in the Discussion.
Derivation of the expression for viability
For modelling the in vitro experiments of tightly age-synchronised parasites, we use Eq. 4. The
solution to Eq. 4 subject to an initial condition N¯(0) = N¯0 is:
N¯(t) = N¯0e−
∫ t
0 k(C(τ),S(τ))dτ , (12)
where we have explicitly presented the killing rate k as a function of DHA concentration C
and stress S, both of which are functions of time (following initiation of drug exposure). DHA
concentration C(t) as a function of time due to in vitro decay is given by
C(t) =C0e
− ln(2)t1/2 t , (13)
where C0 is the initial dug concentration and the in vitro half-life of DHA (t1/2) was measured
to be about 8 hours (21).
For a drug pulse with a duration of Td hours in a given stage of the parasite life cycle, the
total number of iRBCs , Nd , at the time of data collection (during the trophozoite stage in the
next life cycle) is given by
Nd = rN¯0e−
∫ Td
0 kdτ + N¯0(1− e−
∫ Td
0 kdτ), (14)
where k’s dependence onC(τ) and S(τ) is now implicit. The first term represents the number of
iRBC with live parasites (having expanded by factor r, the parasite multiplication factor), while
the second term represents the number of non-viable parasites. For the control case (no drug),
the number of parasites, Nc, is given by Eq. 14 with k= 0 (Nc = rN¯0). For the background case
(all parasites killed due to super-maximal exposure), the number of parasites, Nb, is given by
Eq. 14 with k→ ∞ (Nb = N¯0). Substituting these two expressions back into Eq. 14, we have
Nd = Nce−
∫ Td
0 kdτ +Nb(1− e−
∫ Td
0 kdτ), (15)
which can be rearranged to give
e−
∫ Td
0 kdτ =
Nd−Nb
Nc−Nb . (16)
The right-hand side is precisely the parasite viability (V ) as defined in the in vitro experiments
(7, 9). Therefore we have
V (C0,Td) = e−
∫ Td
0 k(C(τ),S(τ))dτ , (17)
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where the dependence of V on the initial DHA concentration C0 is established through Eq. 13.
Furthermore, we identify φ =
∫ Td
0 k(C(τ),S(τ))dτ as the cumulative drug effect. We have iden-
tified the parasite viability as a function of the cumulative drug effect arising from a dynamic
mechanistic model, allowing us to fit our model to available viability data, and then use the
estimated parameters to perform detailed PK–PD simulations in an in vivo context.
Statistical methods
Estimates of the model parameters (λ , γ , α , β1, and β2), for each parasite stage (early ring,
mid-ring, early trophozoite and late trophozoite), were obtained using nonlinear mixed effect
(NLME) modelling to fit Eq. 17 separately to the viability data for each stage. For each stage,
the data with different drug concentrations was fitted simultaneously. (Note that the stage-
dependent estimate of γ suggested a very limited variation (see Table S1) and was thus fixed
to be the mean of the four estimates in Table S1 later to reduce uncertainty; main results in the
paper were based on a fixed γ .) To account for the dependency between duplicate measure-
ments, the residual error term was partitioned into between- and within-duplicate components,
that were assumed to be uncorrelated and normally distributed with means of zero and vari-
ances σ2b and σ
2
w, respectively. The M3 method was used to account for viability data below
the quantification limit of 0.005 (22).
Model-based 95% confidence intervals were calculated using asymptotic standard errors
(square root of the inverse Fisher information) as follows: estimate ± 1.96 × asymptotic stan-
dard error. 95% parametric bootstrap confidence intervals for the model parameters (Tables
1 and S1) and predictions (Figs. 2 and S1–S3) were calculated by: (1) generating 500 para-
metric bootstrap datasets by simulating from the fitted NLME model; (2) obtaining bootstrap
estimates of the model parameters and predictions by re-fitting the NLME model to each para-
metric bootstrap dataset; and (3) calculating basic bootstrap confidence intervals for each pa-
rameter and prediction: (2 × estimate – 97.5th percentile of bootstrap estimates, 2 × estimate
– 2.5th percentile of bootstrap estimates) (23). Parametric prediction intervals for a new via-
bility measurement (Figs. 2 and S1–S3) were calculated at the observed pulse durations and
DHA concentrations by: (1) simulating 500 viability datasets from the fitted NLME model;
and (2) calculating the 2.5th and 97.5th quantiles of the viability measurements simulated at
each observed pulse duration and DHA concentration.
NONMEM 7.3.0 (ICON Development Solutions, Ellicott City, MD) and Perl-speaks-NONMEM
3.7.6 (24) were used to perform the NLME modelling of the viability data and obtain asymp-
totic standard errors; and to perform the simulation-estimation procedure required to construct
the 95% parametric bootstrap confidence intervals, and the simulations necessary to calculate
95% parametric prediction intervals. MATLAB (version 2014b; The MathWorks, Natick, MA)
was used to summarise and visualise the fitting results.
Results
Fitting the model to viability data
Fig. 2 shows the fitting result for the early ring stage. Results for the other stages are provided
in Figs. S1–S3. Parameter estimates and confidence intervals (CI) are given in Table 1. The
model captures the data very well, in particular the dependence of viability on drug exposure
time, which is the key advance we require.
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Figure 2: Results of fitting the model to viability data (early ring stage). The initially applied
DHA concentration is indicated in the title of each panel. Open circles (appearing in duplicate)
are the repeated measures of viability by (initial) drug concentration and exposure duration.
Black curves show the best-fits of the model with 95% confidence intervals (CI) and 95%
prediction intervals (PI).
Drug concentration-killing rate curves and stage-dependency
The overall impact of parasite killing is primarily determined by the drug concentration-killing
rate curve, which we now consider to be a function of exposure time, generalising the usual
modelling assumption that the killing rate is an instantaneous function of drug concentration.
Fig. 3 shows the modelled evolution of the concentration-killing rate curve for the four different
life-stage of the parasites used in Fig. 1. Except for the early ring stage, for which the curve
reaches its steady state very quickly, the delayed process of approaching the steady-state killing
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rate curve for the other three stages is biologically significant, in particular for the mid-ring
stage where a very strong delay is observed.
Fig. 4 shows the estimates and 95% confidence intervals for the four model parameters λ ,
α , β1 and β2 by stage. The delay in the evolution of the drug concentration-killing rate curve is
primarily determined by the parameter λ (Fig. 4A, Table 1) which reflects the accumulation rate
for stress (Eq. 6). For the early ring stage, λ = 6.25 h−1 and thus S(1 h)> 0.99, indicating that
early rings rapidly succumb to drug exposure. In contrast, the rate of accumulation of stress for
mid-rings is much lower (λ = 0.37 h−1) and it would take over 12 hours of continued exposure
to drug for S to exceed 0.99. Early and late trophozoite stages display similar characteristics in
terms of the rate of accumulation of stress (Fig. 3). The maximum killing rate α (Fig. 4B) shows
a significant reduction for (early and mid) rings compared to (early and late) trophozoites,
suggesting that young parasites may be more resistant to DHA than mature parasites once
(or even when) the killing effect has reached a steady state. The parameters related to the
concentration required to achieve the half-maximal killing rate, β1 and β2, also exhibit stage-
specificity (Fig. 4C,D). In particular, the stationary half-maximal killing concentration (β2,
Fig. 4D) shows that ring-stage parasites exhibit a higher sensitivity to drug at steady state
than trophozoites. However, it must be remembered that, particularly for mid-ring stages, the
progress towards that steady-state (governed by λ ) is slow, and the net effect of the dynamics
of drug-induced killing is best understood through Fig. 3.
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Figure 3: Model results showing the evolution of the drug concentration-killing rate curve with
drug exposure duration for different stages. The time after drug exposure t is indicated in the
legend. Note that the y-axis scale differs for different stages.
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Incorporating the delayed drug effect into PK-PD modelling
Having established the applicability of our model to the in vitro data, we now consider the
potential implications for the in vivo application of artemisinin-based medication. We do so by
incorporating the time-dependency on the killing rate into the general PK–PD framework (Eq.
3) where we allow for realistic drug pharmacokinetics (PK) and a general age-structure for the
parasites.
We begin by considering mid-ring stage parasites treated with a single dose of artesunate
(2mg/kg). The plasma DHA concentration C(t) displays biphasic behaviour (6):
dC
dt
=
{ Cmax
tm
, 0≤ t < tm
− ln(2)t1/2 C, t ≥ tm
(18)
where Cmax is the maximum achievable concentration and tm indicates the time at which that
maximum concentration is achieved. Note that the half-life, t1/2, refers to the in vivo half-life
of drug, which is much smaller than that measured in vitro (21). Cmax = 2820 nM, tm = 1 h and
t1/2 = 0.9 h as per (2, 21). The simulated PK data is shown in Fig. 5A (upper panel).
The middle and lower panels of Fig. 5A shows the time series for the stress, S, and killing
rate, k, as a result of the changing DHA concentration. The black curves are generated using
λ = 0.37 h−1, the best-fit estimate from fitting the model to the in vitro data for the mid-ring
stage (Table 1). Decreasing λ will delay the increase of S and in turn lead to a smaller and
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shortened killing rate profile (red curves in Fig. 5A), while increasing λ will do the opposite
(blue curves in Fig. 5A). We thus consider a lowering of λ as a potential manifestation of
(stage-specific) artemisinin-resistance. Conversely, λ = 1 implies that parasites accumulate
stress rapidly and are rendered non-viable at the stationary rate (givenC(t)) soon after initiation
of the drug pulse.
Under the model, the killing rate k is now a function of two variables (as clearly shown
by Eq. 17), the drug concentration C(t) and the modulatory stress S(t). We can represent this
graphically by displaying the killing rate as a trajectory on a surface in (C,S)-space (Fig. 5B).
In this representation, we can clearly see the effect of λ on the evolution of the killing rate—the
trajectory corresponding to a smaller λ has less time (controlled by S in the model) to climb up
the killing rate surface even when the achievable DHA concentration remains the same.
We can also consider the net cumulative effect of the drug-pulse. As defined in Materials
and Methods, φ =
∫ Td
0 k(C(τ),S(τ))dτ represents the cumulative killing rate or cumulative drug
effect, which is commonly used to indicate drug efficacy. In the in vivo simulation, φ is simply
the area under the effective killing rate curve (i.e. the area under the curve in the lower panel of
Fig. 5A). For mid-ring parasites with λ = 0.37, the cumulative drug effect (Fig. 5C, black bar)
corresponds to a reduction in viability of approximately 99.75% over the drug-pulse. Further
numerical exploration indicates that a roughly threefold increase or decrease in λ leads to a
significant difference in the cumulative drug effect (Fig. 5C, blue, red bars) and in turn a few
orders of magnitude difference in viability.
In summary, the results presented in Fig. 5 indicate that the temporal drug effect signifi-
cantly affects the in vivo parasite killing and thus should be considered in model-based pre-
diction of clinical treatment. Furthermore, the visualisation of the killing rate trajectory on
the (C,S)-plane surface suggests a clear evolutionary strategy for the parasite to escape drug
pressure, particularly given the short elimination half-life of artemisinin and its derivatives.
An ability to “outlast” the short drug pulse provides an effective means of escape, quite dis-
tinct from any changes in susceptibility as are typically considered by a change in the maximal
killing rate or drug concentration required to achieve half-maximal killing.
To fully explore the consequences of accumulation effects on the pharmacodynamics of an-
timalarial treatment, we simulate the time course of total viable parasite count under a standard
AS7 dosing regimen (i.e. a dose of 2 mg/kg artesunate every 24 hours for 7 days) for both the
3D7 strain and a hypothetical strain which exhibits a slower rate of stress development during
the mid-ring stage. Some key simulation details are provided in the caption of Fig. 6. We ini-
tiate the simulation with 1012 parasites per patient with a normally distributed age distribution
with mean 10 h p.i. and standard deviation 2 h p.i. (Fig. 6 (inset)). For the laboratory 3D7
strain, the model predicts that effective parasite clearance is achieved immediately following
the third dose of artesunate (at 48 hours in the model, Fig. 6 green curve). In contrast, for
the hypothetical strain which exhibits a slower development of the stress response during the
mid-ring stage (i.e. λ is reduced for this, but no other, stage), we observe a clear and substan-
tial delay in parasite clearance. In detail, the red curve in Fig. 6 shows the parasitaemia curve
for a “resistant” strain that has λ = 0.1 h−1 for the mid-ring stage (with all other parameters
(across all stages) unchanged). This simulation has an a priori rationale given previous studies
that indicate that field-isolates from Pailin (Western Cambodia) display a reduced sensitivity
to artemisinin-based therapies during the ring-stage of infection (6, 8, 9). We note that while
this simple simulation does not model the process of splenic clearance, its behaviour is consis-
tent with clinical observations of a 1.5 – 2 times longer time to clearance for resistant strains
compared to sensitive strains (6).
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Figure 5: Incorporation of the time-dependent killing rate into the PK–PD model. We study
the mid-ring stage for illustrative purposes. Parameter values are taken from Table 1. Panel
A shows the simulated in vivo DHA concentration profile (upper panel), the kinetics for the
modulatory stress variable S (middle panel, black curve, λ = 0.37) and the transient killing rate
k (lower panel, black curve, λ = 0.37) induced by the drug pulse. The middle and lower panels
also show how S and k evolve if λ is higher (blue) or lower (red). Panel B presents the killing
rate surface as a function of DHA concentration, C, and the stress, S, and the projection of the
trajectory of the effective killing rate (i.e. a projection of the curves in Panel A (lower panel))
onto the surface. Panel C shows the area under the killing rate curve, an indication of the total
amount of killing achievable over the course of the drug pulse.
Discussion
Artemisinin resistance has arisen as the major impediment to the continued success of malaria
control programs. With new drugs likely to be some time away from licensure and widespread
use, how we maintain the effectiveness of artemisinin-based therapies is an important and ur-
gent problem to resolve. In this paper, we have introduced a novel mathematical model that
allows for the detailed investigation of the time-dependent response of P. falciparum parasites
to the artemisinins. We have established the significant influence of the parasite stress response
on killing and incorporated this into a simulation of in vivo parasite clearance. This is the first
study to our knowledge to incorporate the novel time-dependent drug effect into a fully mecha-
nistic PK–PD model, and constitutes an essential step towards development of a comprehensive
framework that can be used to optimise existing dosing regimens.
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Figure 6: Simulation of parasite killing under a standard treatment of 2mg/kg artesunate every
24 hours. The inset shows the age distribution of total 1012 parasites (per patient) at the start of
treatment (∼ N(10,22)). The parasite multiplication factor is assumed to be 10, which means
that 10 new parasites are produced once a parasite reaches 48 h p.i.. PK profile is a series of
repeated DHA concentration profile every 24 hours (i.e. repeated simulations of DHA concen-
tration profile in Fig. 5A upper panel). The black triangles indicate when the doses are given.
The green curve corresponding to the laboratory 3D7 strain is generated using the parameters in
Table 1, while the red curve is generated using the same set of parameters except for reducing
λ for mid-ring stage to be 0.1h−1 to simulate a more resistant strain. With limited information,
we simply divide 48 hours’ life cycle into early ring (0–6 h p.i.), mid-ring (6–26 h p.i.), early
trophozoite (26–34 h p.i.) and late trophozoite (34–48 h p.i.) in the simulation. Modulatory
variable S is assumed to follow Eq. 6 only when DHA concentration C ≥ 0.1 nM, and S is
immediately reset to zero when DHA concentration drops below 0.1 nM.
Validated against detailed in vitro experimental data (7, 9), the key feature introduced in
our model is the concept of dynamic (accumulating) stress (S), and the parameter governing
the time scale of that process (λ ). The time-evolution of stress determines the development
of the killing rate and therefore the probability of parasite survival (as assessed in vitro by
viability). This conceptualisation of stress has been shown to not only capture the in vitro
viability data published in (7) but also identify the relative contributions of drug concentration
and stress response in determining the effective killing effect.
Specifically, the estimate for λ , which determines the strength of the delay, shows that mid-
ring stage 3D7 parasites exhibit a substantially more delayed response to DHA exposure than do
other stages. This is consistent with the original analyses presented in Klonis et al. (7), where
a semi-mechanistic (but not dynamic) Cumulative Effective Dose (CED) model was used for
interpretation of stage-specific drug effects. Klonis et al. also reported an unexpected finding
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that early-ring parasites exhibited a hypersensitivity to DHA compared to mid-ring parasites.
Our model results (Fig. 4) show that a rapid induction of maximal killing (i.e. a rapid increase
in S), rather than a large increase in the magnitude of the maximum killing rate itself, is the
primary explanation for this hypersensitivity.
We also examined through simulation of the full PK–PD model how a cumulative drug re-
sponse affects in vivo parasite dynamics. We considered the standard AS7 artesunate treatment
regimen (a dose of artesunate every 24 hours for 7 days). Parasites that are more able to with-
stand exposure (i.e. that have a lower λ ) during the mid-ring stage remain in circulation for a
significantly greater period of time, with PD profiles that reflect those from patients infected
with resistant strains. These results agree with those we have previously presented using the
CED-model (Figure 7 in (9)), but we emphasise that the results presented here (Fig. 6) arise
from a fully mechanistic PK–PD model. This is an important distinction as, by construction,
our PK–PD model accounts for the ageing and natural replication dynamics of the parasite
population, the time-varying nature of the drug-concentration, and the interaction (killing) be-
tween parasite and drug in a self-consistent and biologically realistic way. This provides us
with enhanced predictive power when compared to the CED-model, which while empirically
useful, was not well-suited to in vivo simulation. We emphasise that our in vivo simulations
provide predictions of the number of viable parasites. However, in vivo assays cannot dis-
tinguish between viable and non-viable parasites, nor detect sequestered parasites. As such,
further advances in experimental assays are required to fully test the predictions from these
simulations.
We have referred to the modulatory variable, S, throughout the paper as a “stress”. We
have done so to provide guidance as to possible biological interpretations of S, but for now
an incomplete understanding of the mechanism of action of the artemisinins limits the de-
gree to which our phenomenologically-based model can be correlated with specific biological
stresses induced by exposure to artemisinins. Recent work (25, 26) confirms earlier studies
(27) suggesting that artemisinins exert their activity by alkylating multiple targets within the
parasite. Reports of growth retardation, quiescence and dormancy following artemisinin expo-
sure (28, 7, 9, 29) are reminiscent of the cytostatic stress response observed in other organisms
(30, 31). Further developments in understanding the mechanistic underpinnings of artemisinin
activity are required to further refine our model for “stress”. The details of any of these pro-
cesses, were they to be confirmed to be associated with cumulative drug effects, would be
able to be incorporated into our model in a straightforward manner through adjustment of the
equations governing the time-evolution of kmax and Kc.
An immediate implication of our model concerns the possible mechanism by which the
malaria parasite attains resistance to artemisinin. Drug-resistance is typically characterised
by an increase in the drug concentration required (in vitro or in vivo) to achieve maximal (or
half maximal) killing. However, our exploratory analysis suggests that increasing tolerance to
stress (i.e. reducing λ ) can also underpin drug escape. Indeed, the experimental results from
(9) in which resistance may be overcome through application of proteasome inhibitors such
as Carfilzomib support this possibility. Furthermore, if such a mechanism where at play, then
long-lived drugs acting on the same (or a similar) pathway, and subject to the same “resistance”
mutations would not result in a resistant-phenotype when applied for extended periods (as S
would still saturate and a high rate of killing would be achieved). This is precisely the behaviour
observed for OZ439 (half-life over 10 hours) in recent experiments (21).
The model we have introduced, while overcoming restrictions of the standard PK–PD ap-
proach and successfully capturing the complex dynamics observed in (7) for the 3D7 strain, has
a number of limitations. Most importantly, Eq. 3 assumes a drug concentration-independent in-
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crease in S while C >C∗ and then an instantaneous return to zero when the drug concentration
drops below C∗. However, this simple approach to modelling the stress, S, reflects the current
limitations on our understanding of the mechanism of action of the artemisinins. With further
data on how the drugs act, the dynamics of stress in the model can be adjusted to reflect the
improved understanding. One important avenue to pursue is to examine how parasites that sur-
vive exposure to an initial drug pulse respond to a subsequent drug pulse. Does their “stress”
(S) return to zero, or do they display some memory of previous exposure, and so presumably
succumb more quickly upon subsequent exposure? If such recovery exists, what is the typical
time-scale in relation to the life-cycle? Such possibilities are 1) able to be probed experimen-
tally using the techniques of (7, 9); and 2) able to be readily incorporated into more complex
models of the form introduced in this paper. Another area for improvement in the approach
taken here is in translating from the in vitro to in vivo situation. For example, our simple sim-
ulations assume there is no killing of parasites due to immune response mechanisms triggered
within the host. While the immune response is unlikely to play a major role during the early
stages of infection, as infection progresses its effects would be anticipated to become more sig-
nificant. Therefore, given the fact that both the drug effect and immune response are dynamic
in nature, it will be important to explore how differences in the timing of drug application and
activation of various immune mechanisms impact upon parasite clearance and optimisation of
drug regimens. In the meantime, our results provide new insight into how P. falciparum re-
sponds to drug. Our model provides an enhanced predictive platform for evaluating the likely
efficacy of alternative artemisinin-based drug regimens, directly contributing to the efforts to
maintain effective control of malaria.
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Figure S1: Results of fitting the model to viability data (mid-ring stage). The applied DHA
concentration (which then decays) is indicated in the title of each panel. Empty circles are
viability data points and duplicate data points for each condition are shown. The black curves
are best-fits with 95% confidence intervals (CI) and 95% prediction intervals (PI).
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 0 nM
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 0.6 nM
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 1.2 nM
0 2 4 6
Vi
ab
ilit
y 0
0.2
0.4
0.6
0.8
1
DHA = 2.4 nM
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 4.9 nM
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 9.8 nM
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 19.5 nM
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 39.1 nM
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 78.1 nM
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 156.3 nM
Drug exposure time in early trophozoite stage (h)
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 312.5 nM
0 2 4 6
0
0.2
0.4
0.6
0.8
1
DHA = 625 nM
data
model fit
95% CI
95% PI
Figure S2: Results of fitting the model to viability data (early trophozoite stage). The applied
DHA concentration (which then decays) is indicated in the title of each panel. Empty circles
are viability data points and duplicate data points for each condition are shown. The black
curves are best-fits with 95% confidence intervals (CI) and 95% prediction intervals (PI).
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Figure S3: Results of fitting the model to viability data (late trophozoite stage). The applied
DHA concentration (which then decays) is indicated in the title of each panel. Empty circles
are viability data points and duplicate data points for each condition are shown. The black
curves are best-fits with 95% confidence intervals (CI) and 95% prediction intervals (PI).
Table 1: Results of fitting the model to viability data Viability data are for the 3D7 strain (7). γ
is fixed to be 1.7892 based on estimates in Table S1. The model-based 95% CI and parametric
bootstrap 95% CI are introduced in Materials and Methods.
Parameter (unit) Estimate SE Model-based 95% CI Parametric bootstrap 95% CI
Early ring stage
λ (h−1) 6.2504 0.5745 (5.1243, 7.3765) (1.8587, 9.5201)
γ 1.7892 (fixed)
α (h−1) 1.6915 0.1378 (1.4215, 1.9616) (1.2944, 1.8475)
β1 (nM) 990.84 373.49 (258.81, 1722.9) (-20377, 1876.5)
β2 (nM) 12.519 1.0631 (10.435, 14.602) (10.560, 13.553)
Mid-ring stage
λ (h−1) 0.3729 0.1406 (0.0974, 0.6485) (0.2515, 0.5035)
γ 1.7892 (fixed)
α (h−1) 1.1224 0.2455 (0.6412, 1.6036) (0.6934, 1.3371)
β1 (nM) 224.39 112.12 (4.6466, 444.14) (117.37, 301.69)
β2 (nM) 9.97×10−4 1.26×10−4 (7.5,12.4)×10−4 (9.8,10.1)×10−4
Early trophozoite stage
λ (h−1) 1.2290 0.2249 (0.7882, 1.6698) (0.6331, 1.8059)
γ 1.7892 (fixed)
α (h−1) 5.7434 0.7460 (4.2813, 7.2054) (1.8799, 7.2729)
β1 (nM) 317.64 86.143 (148.80, 486.48) (-9.4144, 462.98)
β2 (nM) 39.570 4.6038 (30.546, 48.593) (29.315, 46.842)
Late trophozoite stage
λ (h−1) 2.0906 0.2909 (1.5203, 2.6608) (1.4406, 2.6302)
γ 1.7892 (fixed)
α (h−1) 2.8626 0.1591 (2.5508, 3.1744) (2.2851, 3.2810)
β1 (nM) 740.02 178.77 (389.64, 1090.41) (160.00, 1071.6)
β2 (nM) 41.405 3.6606 (34.230, 48.580) (35.459, 45.629)
23
Table S1: Results of fitting the model to viability data. The model-based 95% CI and parametric
bootstrap 95% CI are introduced in Materials and Methods in the main text. γ is allowed to
vary for different stages.
Parameter (unit) Estimate SE Model-based 95% CI Parametric bootstrap 95% CI
Early ring stage
λ (h−1) 6.2913 0.5294 (5.2537, 7.3288) (-0.2036, 9.5726)
γ 1.7703 0.1694 (1.4383, 2.1022) (1.5789, 1.9794)
α (h−1) 1.6987 0.1484 (1.4078, 1.9896) (1.0569, 1.8591)
β1 (nM) 1013.0 361.39 (304.71, 1721.3) (-76380, 1909.0)
β2 (nM) 12.734 2.0654 (8.6858, 16.782) (7.5398, 14.927)
Mid-ring stage
λ (h−1) 0.3638 0.1359 (0.0965, 0.6301) (0.2216, 0.5375)
γ 1.7433 0.2889 (1.1770, 2.3096) (1.1612, 2.0665)
α (h−1) 1.1472 0.2806 (0.5973, 1.6971) (0.3129, 1.4028)
β1 (nM) 222.94 94.830 (37.076, 408.81) (113.78, 302.00)
β2 (nM) 9.86×10−4 4.66×10−5 (8.90,10.8)×10−4 (9.70,10.0)×10−4
Early trophozoite stage
λ (h−1) 1.2720 0.2163 (0.8480, 1.6959) (0.8361, 1.7458)
γ 2.0864 0.2023 (1.6900, 2.4829) (1.6895, 2.3859)
α (h−1) 4.8326 0.6615 (3.5361, 6.1291) (2.3239, 5.8950)
β1 (nM) 280.55 72.477 (138.50, 422.60) (60.544, 387.98)
β2 (nM) 26.711 6.3515 (14.262, 39.160) (13.965, 34.734)
Late trophozoite stage
λ (h−1) 2.3076 0.3986 (1.5263, 3.0890) (1.4744, 2.8986)
γ 1.5568 0.0799 (1.4001, 1.7134) (1.4097, 1.6828)
α (h−1) 3.3892 0.3381 (2.7265, 4.0519) (2.1815, 4.0184)
β1 (nM) 1132.2 469.61 (211.78, 2052.6) (-306.63, 1704.5)
β2 (nM) 60.559 11.012 (38.976, 82.141) (34.002, 74.003)
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